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for hospital admission and this trend is expected to persist due to the
ageing of the world population [1]. Although advances in HF therapy
[2], the prognosis of these patients remains poor and further efforts
are required to enable an early diagnosis, risk stratification and person-
alized therapies. Albeit our genetic profile strongly contributes to deter-
mine HF risk, growing evidence indicates that epi-genetic changes -
including DNA methylation, histone modifications and non-coding
RNAs (ncRNAs) - may act as fundamental biological layers regulating
gene expression and cardiovascular phenotype over the lifetime.
Among the ncRNAs family, microRNAs (miRNAs) have been extensively
investigated in the setting of cardiovascular disease and HF. MiRNAs are
~22-nucleotide long structures involved in different cellular processes
through the blockade of messenger RNA translation by binding at the
complementary 3′-untranslated region and modulating gene expres-
sion at the post-transcriptional level [3]. A wealth of miRNAs were re-
ported to have a role in cardiac remodeling, hypertrophy, hypoxia,
and apoptosis eventually fostering HF development [4–6]. Whether
miRNAs can be employed as reliable HF biomarkers remains to be
fully elucidated.
In this issue of the Journal, Stojkovic et al. investigated the role of the
liver-specific miRNA-122 as a marker for prognosis and risk stratifica-
tion in a case-control cohort of 40 patients with HF with reduced ejec-
tion fraction (HFrEF) who died during the follow-up (cases) and 36
survivors (controls) [7]. Among 84 miRNAs evaluated in the screening
phase, only 3 miRNAs were differentially expressed among the 2
groups: miRNA-122, −423, and − 126. The levels of these miRNAs
were then further assessed in a validation cohort of 234 patients with
HFrEF at the time of outpatient clinic admission. Seventy-six patients
died during follow-up (median 3.2 years), of whom 52 for a cardiovas-
cular cause. Levels of miRNA-122 and -423 were found higher among
non-survivor patients and both displayed positive correlations with N-DOI of original article: https://doi.org/10.1016/j.ijcard.2019.11.090.
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Epiphenomenon or causal?, International Journal of Cardiology, https://dolevels. Furthermore, miRNA-122 and -423 were shown to be indepen-
dent predictors of all-cause mortality, even after adjustment for rele-
vant confounders such as sex, age, left ventricular ejection fraction,
NT-proBNP, diabetes, glomerular filtration rate, NYHA class, right ven-
tricular dysfunction, and previous MI. Finally, the authors found differ-
ent cut-off levels for the two miRNAs (12 and 3694 copies/μL plasma,
respectively), which were able to identify patients at risk of all-cause
mortality and cardiovascular death. Moreover, an additive effect in
predicting mortality was found when both miRNAs were above the re-
spective cut-offs. The interesting aspect of the research, therefore, relies
on the fact that whenmiRNA-122 and -423were separately included in
the prediction model, only miRNA-122 significantly improved the pre-
diction for all-cause and cardiovascular mortality on top of classical
risk factors and NT-proBNP [7].
The paper by Stojkovic et al. provides new evidence on the role of
epigenetic biomarkers, namely miRNAs, in HFrEF patients. While previ-
ous work has extensively investigated the role of miRNAs in HF diagno-
sis and stratification, only few studies focused on their ability to predict
prognosis [6,8,9]. The latter aspect is of paramount importance as an in-
creasing number of patients will suffer from HFrEF in the decades to
come, and reliable circulating biomarkers are in high demand.
MiRNA-122 is the most abundant ncRNA in the liver, where it regu-
lates genes involved in cholesterol and fatty acid metabolism. Here,
miRNA-122 was found to independently predict all-cause mortality,
even after adjustment for right ventricular dysfunction, cholinesterase
and gamma-GT, suggesting that factors other than fluid congestion
and liver injury may contribute to explain the association of miR-122
with mortality. In the present study the authors postulated that high
levels of miR-122 in HFrEF likely reflect liver damage due to chronic
congestion. However, liver-derived miR-122 may also exert its biologi-
cal effects on the myocardium. Indeed, recent work has shown that in-
hibition of mir-122 prevents cardiomyocyte apoptosis in an
experimental model of atrial fibrillation [10]. In other words, upregula-
tion ofmiR-122 driven by liver injurymay lead to detrimental effects on
the heart, thus feeding a noxious vicious cycle. Moreover, myocardial
expression of miR-122 may also contribute to the pathophysiology of
HF. Although these data suggest a central role of this miR in HF, in theal., MicroRNA-122 in heart failure with reduced ejection fraction:
i.org/10.1016/j.ijcard.2019.12.038
2 Editorialstudy by Stojkovic et al.miRNA-122wasnot found tobe an independent
predictor of cardiovascular mortality. However, miRNA-122 levels
showed a significant correlation with NT-proBNP and significantly im-
proved the prognostic model with respect to all-cause and cardiovascu-
lar mortality [7].
It is then clear that miRNA-122 might be considered when evaluat-
ing patientswith HFrEF in order identify those patientswith congestion,
liver injury, and at high risk for death. There remain, however, few is-
sues to be addressed before considering mir-122 as a potential bio-
marker to be employed in the clinical setting. Most of studies
conducted so far, including that by Stojkovic et al., did not use a large
miRNA panel for screening, thus leading to a potential selection bias.
Additionally, the diagnostic and prognostic power of miRNAs should
be always compared to currently available, gold standard parameters,
such as NT-proBNP, in order to highlight their incremental value in
predictingHF-related events. Finally, the lack of consistency in the avail-
able studies is worth being discussed as many factors might contribute
to these results [3]. For example, different anticoagulants contained in
the tubes for blood collection as well as the biological material used
for the analysis (plasma, serum, or whole blood) may affect miRNA ex-
pression. Unfortunately, we still lack standardized approaches for the
assessment of circulating miRNAs, this also represents a major con-
founder when comparing different studies. Overall, evidence discussed
so far does not allow to fully understandwhethermiR-122 plays any ac-
tive role in HFrEF, or whether its upregulation reflects liver damage as
the result of fluid congestion.
In conclusion, the paper by Stojkovic et al. provides novel insights on
miR-122 as an early biomarker of liver injury and mortality in patients
withHFrEF. Further studies in larger cohorts are urgently needed to rep-
licate these results.Please cite this article as: A. Bonaventura, A. Vecchié, S. Costantino, et
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